Key Points Indivior is already profitable and cash-generative, and is set to grow significantly in 2026. Its key medication's delivery system offers opioid use disorder patients more reliable outcomes. 10 stocks we like better than Indivior Plc › Shares in Indivior Plc (NASDAQ: INDV) were up by 15.5% at 1 p.m. ET today after management released an excellent set of third-quarter results, upgraded its full-year guidance, and served notice that its "Indivior Action Agenda" three-phase plan is generati ...

Indivior (INDV) moved up 11 positions on Monday into the 46th spot on Barchart’s Top 100 Stocks to Buy. The opioid-treatment pharmaceutical company was one of only eight stocks in the top 50 to gain at least 10 spots in yesterday’s trading. The Barchart Technical Opinion is a Strong Buy. Up nearly 13% in the past month and 139% over the past 12 months, momentum is definitely on its side. More News from Barchart UK-based consumer products company Reckitt Benckiser (RBGLY) spun off Indivior in December 20 ...